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The first efficacy trials—named STEP—of a T cell vaccine against HIV/AIDS began in 2004. The unprecedented structure
of these trials raised new modeling and statistical challenges. Is it plausible that memory T cells, as opposed to
antibodies, can actually prevent infection? If they fail at prevention, to what extent can they ameliorate disease? And
how do we estimate efficacy in a vaccine trial with two primary endpoints, one traditional, one entirely novel (viral load
after infection), and where the latter may be influenced by selection bias due to the former? In preparation for the
STEP trials, biostatisticians developed novel techniques for estimating a causal effect of a vaccine on viral load, while
accounting for post-randomization selection bias. But these techniques have not been tested in biologically plausible
scenarios. We introduce new stochastic models of T cell and HIV kinetics, making use of new estimates of the rate that
cytotoxic T lymphocytes—CTLs; the so-called killer T cells—can kill HIV-infected cells. Based on these models, we make
the surprising discovery that it is not entirely implausible that HIV-specific CTLs might prevent infection—as the
designers explicitly acknowledged when they chose the endpoints of the STEP trials. By simulating thousands of trials,
we demonstrate that the new statistical methods can correctly identify an efficacious vaccine, while protecting against
a false conclusion that the vaccine exacerbates disease. In addition to uncovering a surprising immunological scenario,
our results illustrate the utility of mechanistic modeling in biostatistics.
Citation: Wick WD, Gilbert PB, Self SG (2006) On modeling HIV and T cells in vivo: Assessing causal estimators in vaccine trials. PLoS Comput Biol 2(6): e64. DOI: 10.1371/
journal.pcbi.0020064
Introduction
The ﬁrst generation of vaccines against the human
immunodeﬁciency virus (HIV), designed to prevent HIV
acquisition by stimulating neutralizing antibodies, failed to
protect in efﬁcacy trials [1]. Second-generation vaccines have
been designed to elicit HIV-speciﬁc cellular immune
responses [2]. These candidates are supported by evidence
that so-called killer T cells—the cytotoxic T lymphocytes
(CTLs), bearing the CD8 membrane-molecule, that can react
to and kill infected target (IT) cells—play a crucial role in
controlling HIV infection [3–11].
The ﬁrst efﬁcacy trial, named STEP, of a T cell–directed
HIV vaccine began in December 2004; it is being conducted
by Merck Research Laboratories in collaboration with the
HIV Vaccine Trials Network and the Division of AIDS at the
US National Institutes of Health. The candidate vaccine
(MRKAd5) consists of three vectors that can ferry HIV
proteins into human cells (adenovirus serotype-5, encoding
the HIV gag, pol, and nef genes, respectively). The vaccine
elicits broad T cell responses in a majority of vaccinated HIV-
uninfected adults [12]. The STEP trial will randomize 3,000
HIV uninfected volunteers to receive MRKAd5 or placebo in
a 1:1 ratio and follow participants until 100 HIV infections
occur. Mehrotra, Li, and Gilbert [13] provide details of this
trial. A second STEP trial of MRKAd5 with a nearly identical
design will begin in South Africa in 2006.
The co-primary endpoints of the STEP trials are HIV
infection and a clinical measure of disease: setpoint viral load.
The terminology reﬂects the typical course of HIV disease,
which appears ﬁrst as a ﬂu-like illness (called primary viremia
and lasting for about a month), progresses through a stable,
asymptomatic phase (which can last ten years or more), then
(if untreated) progresses to AIDS. The viral load is typically
measured in blood drawn sometime after the primary stage
(and expressed as virions per milliliter, for example). Even
without preventing infection, a vaccine that suppresses viral
load could confer a beneﬁt to the individual, by slowing
progression to AIDS [14,15] and preventing the need for
antiretroviral treatment; and to the community by reducing
HIV transmission [16,17]. The second primary analysis of
STEP compares viral load setpoints among HIV-infected
subjects in the vaccine and placebo groups.
Besides the unprecedented nature of the trials (the ﬁrst to
test a T cell vaccine in humans, to our knowledge), the
nontraditional design presented a statistical challenge.
Because the subjects included in the viral-load comparison
are determined by a post-randomization event, HIV infec-
tion, the analysis is susceptible to selection bias [18,19].
Speciﬁcally, a conventional analysis of viral load differences
would not uniquely assess a causal effect of the vaccine, but
rather a mixture of causal vaccine-effect and the effects of
variables correlated with viral load (e.g., host genetics). The
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vaccinated and infected-placebo groups. For example, selec-
tion bias would occur if the vaccine protects from HIV
infection only vaccinees with a relatively strong immune
system, which implies the infected vaccine group would be
weaker immunologically than the infected placebo group.
Consequently, even if the vaccine has no causal effect on
viremia, the viral loads in the vaccine group would be
expected to be higher than those in the placebo group.
Failing to account for this selection bias would lead to the
incorrect inference that the vaccine harmfully increases viral
load.
In preparation for the analysis of the STEP trials, Gilbert,
Bosch, and Hudgens (GBH) [20] and other investigators
[21,22] developed statistical techniques for assessing a vaccine
effect on viral load that allow for plausible (expert-speciﬁed)
levels of selection bias. However, these papers did not
consider underlying biological mechanisms that could ac-
count for causal vaccine effects. Rather, they simulated
arbitrary effects and studied the purely statistical operating
characteristics of the methodology.
To evaluate the statistical methods in a more biologically
relevant manner, we consider here various mechanistic
hypotheses for vaccine effects. At their present stage of
development, mathematical models of HIV infection and the
immune system have made few compelling predictions,
primarily because of uncertainty about which are the most
important mechanisms and the values of rate-constants.
Nevertheless, models have attained enough maturity that
they can quantitatively reproduce the drop in primary
viremia after appearance of HIV-speciﬁc CTLs, the lag
between peak viremia and peak immune response, the
formation of a steady state, and other aspects of HIV
infection [23–26]. In addition, we can exploit a recent
estimate of the rate at which HIV-speciﬁc CTLs can kill
HIV-infected cells [11]. Building on these developments, we
constructed new stochastic models of primary infection and
the immune response and made a surprising observation: it
does not appear implausible (at least in models) that CTLs
might abort an HIV infection. By using infection as a co-
primary endpoint with setpoint viral load, the designers of
the STEP trials explicitly acknowledged this possibility.
For purposes of discussion, let us distinguish prevention
from eradication of infection. By prevention we will mean
either that no productively infected target (PIT) cells arise
at all, or the pool does not expand beyond some small
number of cells; afterward, it is driven to extinction. The
number of PITs at any time is insufﬁcient to cause disease.
(For HIV, PITs are primarily two other kinds of immune-
system cells: T cells carrying the CD4 surface molecule, and
macrophages. We include the modiﬁer productive in deﬁning
PIT because infected T cells may revert to an unproductive,
or latent, state.) Such a favorable outcome might be
described as a transient infection or as sterilizing immunity,
depending on which assays are employed to detect
exposure. (Finding HIV-derived DNA in latently infected
CD4 T cells, or HIV-speciﬁc CD8þ memory cells, would
point to the former.) Eradication we restrict, consistent with
common usage, to clearing the infection after primary,
symptomatic viremia.
Because CD8 T cells require a priming (activation) step and
an expansion (proliferation) period before they can clear
infected cells, most immunologists regard preventing infec-
tion—as we have deﬁned it—to be unlikely [27]. That
vaccines against simian immunodeﬁciency virus (SIV) have
not prevented infection may be a consequence of the large
inoculums used in the experiments [23]. More relevant to
HIV is the observation of T cell memory to HIV antigens in
frequently exposed but seronegative sex workers in Kenya
[28]. One mechanistic interpretation of this ﬁnding is that a
productive cellular infection was initially established, but was
either cleared by CTLs or went extinct due to chance
(consistent with our models; see below). The transient
infection left behind a small pool of latently infected, resting
CD4 T cells that, due to occasional activation events,
continuously expose the immune system to HIV antigens,
maintaining CTL memory. However, the investigators could
not prove that the HIV-speciﬁc CTLs actually protected these
women. But vaccine-derived or adoptively transferred CTLs
have prevented infection by other viruses; in particular,
Sendai [29] and Ebola [30] in mice. However we may judge
the plausibility of prevention by T cells, as we are interested
here in the impact on statistical estimation, we have to
incorporate some biological mechanism for it into our
simulations.
We have combined stochastic and deterministic models so
as to simulate the impact of T cells both on the probability of
infection given exposure and on viral load assuming
infection, in vaccinated or unvaccinated subjects. Of course,
such a concatenation requires more hypotheses, in particular
about vaccine action. Again, because of the extent of
uncertainty about these mechanisms, we do not claim to
predict the outcome of vaccine trials. Rather, the models
provide cases where an inﬂuence of selection bias is present
or absent, and when present of a magnitude resulting from
biological scenarios rather than ad hoc assumptions. We can
then generate thousands of hypothetical STEP trials, and put
the GBH method to the test.
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Synopsis
In traditional biostatistics, mechanistic modeling of the relevant
biology usually plays no role, because regulatory agencies will not,
quite understandably, license vaccines or drugs on the basis of
theories. But the second wave of trials of HIV vaccines will test two
conjectures simultaneously. The theoretical possibility that these
new, nonclassical, T cell–directed vaccines will prevent some
infections while only ameliorating disease in others required
biostatisticians to invent new ways of estimating vaccine efficacy.
When only the one traditional endpoint—infection—is analyzed, the
randomization to vaccine or placebo groups protects against bias.
But the new techniques required input from experts on the
plausible range of bias introduced by post-randomization selection
(by infected state) for the second analysis. Here mechanistic
modeling can play a role in evaluating the statistical methodology
in biologically plausible settings. By simulating thousands of trials
using their models, Wick, Gilbert, and Self were able to demonstrate
that the methods protected from falsely concluding a harmful effect
of the vaccine on disease. They also noted that the so-called killer T
cells, as opposed to antibodies raised by a traditional vaccine, may
actually be able to prevent some infections—a conclusion rather
surprising for most immunologists and virologists, but which had to
be allowed for when designing the vaccine trials.
Modeling Vaccine EfficacyStatistical Assessment of Causal Vaccine Efficacy of a T Cell
Vaccine
In the STEP trials, two vaccine efﬁcacy parameters will be
assessed; one-minus-relative-risk of HIV infection, and the
difference (placebo–vaccine) in mean viral load setpoint of
HIV-infected subjects, where setpoint viral load is deﬁned
as the average of two log10 plasma HIV RNA levels
measured at month 2 and 3 visits after diagnosis of HIV
infection. The data will be analyzed using an adaption of
the GBH method, which estimates the causal vaccine effect
on viral load while accounting for plausible levels of
selection bias. This technique was developed from the
potential outcomes framework for causal inference [31,32].
In this framework, each trial participant has two potential
HIV infection outcomes: one under assignment to vaccine
and one under assignment to placebo. Following GBH, a
causal effect on viral load can be deﬁned for the
subpopulation of always-infected subjects who would be-
come HIV-infected regardless of randomization to vaccine
or placebo. Such an effect is causal because the always-
infected subpopulations of the two study arms have
identical characteristics except for the vaccine/placebo
assignment, and therefore observed differences are directly
attributable to vaccination. The methods estimate the
average causal effect (ACE) of vaccine on viral load, equal
to the difference in mean setpoint viral loads (placebo–
vaccine) for the always-infected subpopulation. The funda-
mental difﬁculty in evaluating the ACE is the lack of
knowledge about which infected subjects are in the always-
infected group—knowing this would require data on
subjects’ HIV infection outcome both under assignment to
vaccine and under assignment to placebo, but for each
subject only one of these outcomes is observed.
To address the identiﬁability problem, GBH made the
simplifying assumption that the vaccine does not increase the
risk of infection for any subject, and posited a model for
whether an infected placebo recipient with setpoint viral load
Y would have been infected had they been assigned vaccine.
This model is indexed by a sensitivity parameter b, which is
the log odds ratio of infection under assignment to vaccine
comparing two infected placebo recipients with setpoint viral
loads Y and Y   1. A value b ¼ 0 reﬂects the case of no
selection bias, in which case the naive analysis assesses a
causal vaccine effect, and positive (negative) values of b
reﬂect selection bias such that the odds of infection is higher
(lower) for larger setpoint viral loads Y. The parameter b is
ﬁxed by the investigator at each possible value within a
plausible range, and for each b, GBH provided procedures for
estimating ACE(b) with a conﬁdence interval. See Materials
and Methods for the mathematical details. For the ﬁrst STEP
trial, a panel of ten experts proposed a plausible range for b
of log(.5) to log(7); see Discussion section. To be cautious, our
analysis will estimate ACE(b) over a somewhat wider range for
b, namely log(0.37) to log(7.4); i.e., b 2 [ 1,2].
Mechanistic Modeling of HIV, CTLS, and Vaccine Effects
Mathematical models of HIV can be divided into two
classes: the whole-body, deterministic, and the small-volume,
stochastic. The former models are appropriate in a discussion
of steady-state viral load, but inappropriate for treating the
early events in infection [23]. The latter class is capable of
addressing random outcomes after exposure.
Predicting viral load: The whole-body, deterministic model.
For this model class, both the infection process and the
immune system are assumed to have large numbers of cells in
each compartment, meaning a subset of cells sharing all
transition rates. The usage is, however, not bio-geographic (as
in tissue compartments); rather, cells are assumed to mix
uniformly in the body. The dynamics are mass-action and
determined by parameters that express the rate, per unit time
per cell, of a particular transition. In Materials and Methods,
we display all possible transitions and label the corresponding
rate-constants (see Table 1); the rates themselves are given in
Table 2. The ODEs (ordinary differential equations) used for
simulating are consequences of the rates (see Discussion).
Here we describe the processes informally.
For the infection side, a target cell passes through two
stages, the eclipse or IT phase, which lasts about a day, and
the PIT phase, whose length depends on the intensity of
killing by CTLs. Virions are not represented explicitly in the
model, because of their short lifetime in vivo (hours at most);
nor are uninfected target cells, a consequence of the belief
that the cellular immune response—as opposed to target-cell
limitation—controls the infection [9]. Hence, the birth rate of
a new IT is proportional to the number of PITs existing at
that time. The proportionality rate-constant is determined by
the basic reproductive number, R0 (see Equation 7).
On the immune system side, the kinetic model for T cell
dynamics, introduced in [24], implements the programmed-
proliferation scenario, in which CD8þT cells, once activated,
proceed through a sequence of doublings (at least eight)
before reverting to resting status or to being eliminated by
apoptosis. The model contains both naı ¨ve and memory cells.
Memory cells are activated faster, pass more quickly through
the cell cycle, and acquire effector status faster than naı ¨ve
cells. We may modify the basic model to incorporate an HIV-
induced ‘‘memory defect’’ or ‘‘killing defect,’’ (see [24]). (This
option reﬂects the opinion that HIV infection damages the
immune system, particularly by killing CD4 T cells that assist
CTLs and other immune system cells in maturing and
functioning.) Many other aspects of CTLs, such as epitope
speciﬁcity, affect their potency in suppressing HIV [33], but
are not included in our simpliﬁed model. See Modeling the
Cellular Immune Response in Materials and Methods and
Table 3 for the process and Table 4 for the rates.
Figure 1 shows a choice of parameters yielding peak
viremia in a little more time than a month, and steady state in
three months. On a longer timescale, the model displays a
stable steady state (whose existence can be veriﬁed mathe-
matically). To create Figure 1, the resting-cell activation and
CTL activation-and-killing parameters (denoted a and j in
Materials and Methods) were set to about 10
 10, obtained by
scaling the value estimated in [11]. This work analyzed data
Table 1. Transitions of the Infection Process
Type Jump Rate
Infection: Xk ! Xk þ 1 ipk (RnvnYn)
Death: Yk ! Yk   1 dPIT Yk
Progression: Xk ! Xk   1a n dYk ! Yk þ 1 g Xk
DOI: 10.1371/journal.pcbi.0020064.t001
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Modeling Vaccine Efficacyfrom in vitro studies of CTLs suppressing HIV replication in
cell lines, as well as adoptive-transfer studies of CTLs in HIV-
infected patients, and estimated a combined activation and
killing parameter at about 0.3 ll cell
 1 day
 1 (varying by a
factor of about four with the speciﬁcities of the CTLs). This
value must be multiplied by a volume factor to obtain the
whole-body parameter useful here; the factor is roughly 1/
(5.50   10
6): 5 310
6 for the ﬁve liters of peripheral blood and
50 because only 2% of T cells reside in PB (98% residing in
tissues), while the data analyzed in [11] referred to cells in
serum. The rate of activation (labelled a in Materials and
Methods) of resting cells, by professional antigen-presenting
cells, is distinguished in our model from the rate that CTLs
become activated and kill (labelled j), by T cell receptor
engagement with HLA-peptide complexes on target cells.
Due to the lack of studies distinguishing these rates, we used
the same value for both.
With other choices of rate-constants, suitable for other
pathogens targeting different tissues (e.g., inﬂuenza), the PP-
model (programmed-proliferation model) can predict erad-
ication after primary viremia [24,25] (see Figure 2). Key
elements are a faster-growing pathogen (e.g., with a shorter
eclipse period or larger R0) and higher immune system
activation or killing rates. Hence, this conclusion is implau-
sible for HIV (or SIV), at least based on currently available
models.
Can T cells abort an HIV infection? The small-volume,
stochastic model. The prevention question involves different
biology than that for eradication, as well as distinct modeling
challenges. Concerning the biology, depending on the route
of infection, the initial confrontation might be in blood,
lymph nodes, or mucosal tissues. The concentration of
memory T cells will differ in these compartments; as will
the activation and killing rates. For the mucosal route, it is
even conceivable that a special class of memory effector cells
resides in mucosa which can kill immediately upon T cell
receptor engagement but without requiring activation by
antigen-loaded antigen-presenting cells. (The military anal-
ogy would be pickets, guarding against the enemy’s advance
units.) The basic reproductive number (R0) may be different
from the value we adopted when discussing the global
infection, because the concentration of target cells at the
portal may differ from the whole [34]. For example, in rectal
exposure to HIV, the gut is rich in activated, memory CD4þT
cells, the virus’s primary target.
Several other observations about host and pathogen
biology may be relevant to the prevention question.
Virologists have noted that PITs produce a highly variable
number of virions, in the range 50–1,000 per day in the
productive period [35]; also, at least in vitro, only one virion
in 10,000 is infectious (M. Emerman, personal correspond-
ence to WDW). Rampant bottlenecking may characterize
retroviral population dynamics; indeed, some HIV geneticists
Table 2. Rates in the Infection Process
Parameter Meaning Value (for Rates, per Day)
R0 Basic reproductive number 4.0–6.0
dPIT PIT death 0.33
g Progression 1.0
i Infection See Equation 7
K High-level production 100
a
Fmean High-level mean-fraction 0.9
aYields moderate EPV, a variance-to-mean ratio of about 800, and an Ne ’10
5; see [44].
DOI: 10.1371/journal.pcbi.0020064.t002
Table 3. Transitions of the HIV-Specific, CD8 Cellular-Immune-
System Model
Type Jump Rate
Immigration: WNR ! WNR þ 1 f
Mitosis: Wi ! Wi   1,Wiþ1 ! Wiþ1 þ 2 miWi
Death: Wi ! Wi   1, diWi
Reversion: Wi ! Wi   1,Wj ! Wj þ 1 qWi
DOI: 10.1371/journal.pcbi.0020064.t003
Table 4. Rates in the HIV-Specific, CD8 Cellular-Immune-System
Model
Parameter Meaning Value (for Rates, Per Day)
a Resting activation 0.2/V or 10
 10
j Activation/killing 0.2/V or 10
 10
f NR ‘‘immigration’’ See the ‘‘Modeling the cellular
immune response’’ section
dNR NR death rate .00017
dMR MR death rate .333
dCTL CTL death rate .333
q Reversion fraction .05
nd Number of doublings 8
  Naı ¨ve cell-cycles/day 2.0
  Memory cell-cycles/day 4.0
  Naı ¨ve cell-cycles before CTL 4
  Memory cell-cycles before CTL 1
  Memory speed-up factor 7.0
V Volume (stochastic model) 2 20 ll
DOI: 10.1371/journal.pcbi.0020064.t004
Figure 1. Whole-Body, Deterministic Model Suitable for HIV, Showing
Infection and Immune Response; with R0¼4, progression time (IT to PIT),
one day; and a ¼ j ¼ 10
 10
DOI: 10.1371/journal.pcbi.0020064.g001
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Modeling Vaccine Efficacybelieve that the virus population in vivo has a low effective
population size (‘‘Ne’’) [36,37]. Geneticists can provide many
explanations for a low Ne; e.g., periodic selective sweeps, ‘‘bio-
geographic’’ localization of lineages (i.e., in different tissues),
or migration-extinction episodes. (Others doubt that it is low
[38].) Yet another proposal, which we shall call ‘‘extra-Poisson
variation’’ (EPV) and incorporate in our model, attributes the
bottlenecking to the level of the individual PIT. Finally, HIV
epidemiologists have ascertained that the risk of infection
given exposure is surprisingly small, typically in the range 1/
2,000 to 1/200 depending on the mode of transmission and
the population studied [39–41].
Concerning modeling, two aspects of the prevention
problem render the whole-body, deterministic model inap-
plicable. First, the site of the initial struggle may be conﬁned.
If so, the rate parameters for activation and killing must be
suitably rescaled, because they reﬂect the probability of cells
coming together. Consider, for example, one PIT, 10
9 HIV-
speciﬁc, CD8 T cells (1% percent of the CD8 compartment,
an optimistic goal for a vaccine), and activation and killing
rates of about 10
 10 ll cell
 1 day
 1. If we assume the cells are
uniformly distributed in ﬁve liters of peripheral blood (or
several kilograms of tissues), the whole-body, uniformly
mixed model predicts that, as infectious virions are swept
through blood and lymph, an activated CTL will soon
appear—but the impact on the lifetime of the solitary PIT
will be inﬁnitesimal. The reason is that, due to the uniform
mixing hypothesis, the CTL is likely to be far away (i.e., in
another of the ﬁve million microliters of peripheral blood, or
another lymph node). But the ﬁrst CTL may appear, divide,
and function nearby. Imagine a volume drawn around the
initial PIT, just sufﬁcient to enclose one HIV-speciﬁc CTL.
Because vaccine designers have settled on 50 HIV-speciﬁc
CTLs per 10
6 peripheral blood mononuclear cells as an
empirical criterion for an interesting immunogen, we
imagine this volume in the range 2–20 ll. The rate constants
for activation and killing should be rescaled from the value
estimated in [11] by the inverse of this volume—as opposed to
the factor mentioned in the previous section. These rate-
constants will be at least six orders of magnitude larger than
suitable for the whole-body mixed model.
Starting from those two precursors, we can envisage a race
between infection process and immune response. Modeling
such a competition, with small numbers of players, by
deterministic rate equations is out of the question. Both
infection and immune dynamics must be considered stochas-
tic and modeled by jump Markov processes. In similar
situations, branching-type processes have appeared in mod-
eling clonal extinction in multistep carcinogenesis [42] and
the impact of drugs in primary HIV or SIV infection [23].
However, because of the interactions that appear in the
activation and killing rate functions, our processes are not of
the pure-branching type. For example, ‘‘daughters’’ of
different ‘‘parent’’ CTLs are not independent, because they
share in the activity of recognizing or killing the same PITs;
likewise, the different PIT lineages are not independent
because they stimulate and are killed by the same clone(s) of
CTLs. No analytical or numerical techniques are available for
computing the extinction or other probabilities (as for
instance were exploited in [23]); we must rely on simulations.
On the positive side, as we are only interested in outcomes
with peak infection less than some small upper bound (e.g.,
1,000 PITs), simulation is fast (and we do not need the
sophisticated switchover techniques of [26,43].)
To allow for a dynamical explanation of a low effective
population size, as well as the small infection probability
given exposure, we ampliﬁed the basic infection model by
assuming multiple types of PITs (as in [44]). A PIT of type ‘‘k’’
is generated with probability pk and produces virions at rate
vk. Because absent this additional heterogeneity for a ﬁxed
PIT lifetime the number of its ‘‘offspring’’ is a Poisson
random variable, we will refer to this class as exhibiting EPV.
The simplest model (see Equation 11) has three PIT types,
which produce none, one, or many (e.g., 1,000) offspring per
unit time, with a two-parameter probability law arranged to
yield the chosen degree of EPV and so that the third
production level contributes to the mean (e.g., by setting,
with v3¼1,000 and mean¼3, p3¼2.5/1,000). The connection
with Ne is explained in [44]. With these assumptions, the
infection process may be dominated for a time by unlucky
progenitors that have fewer than two offspring, which pushes
the extinction probability close to one [44].
Hence, we chose the PIT-heterogeneity parameters to
generate a low infection-given-exposure, although since
extinction is a dynamic outcome the exact ﬁgure will depend
on other parameters, especially the initial volume (V) and the
basic reproductive number (R0). In Figure 3, we display the
vaccine efﬁcacy (VE) for preventing infection as a function of
volume V, for several choices of R0. The initial condition was
one PIT of type k with probability pk and, in vaccinees, one
HIV-speciﬁc, resting memory cell. The stochastic process was
halted if the infection compartment went extinct, exceeded
1,000, or the time reached 30 days; in the latter cases the
infectionwasdeclaredestablished.Inasizablefractionofcases,
the infection attained more than 100 cells but was eventually
eliminated, demonstrating that CTLs can win the race.
Results
We simulated 500 trials under various hypotheses about
vaccine action. A trial consisted of enrolling subjects and
Figure 2. Whole-Body, Deterministic Model Suitable for a Faster, More
Immunogenic Pathogen (Bacteria or Virus, but not HIV), with R0 ¼ 5
Progession time, 1/4 day; a ¼ 10
 5; j ¼ 10
 9.
DOI: 10.1371/journal.pcbi.0020064.g002
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Modeling Vaccine Efficacysimulating the effect of one exposure per subject, until 100
infections were recorded. To generate a variety of outcomes
reﬂecting the host and viral heterogeneity we would expect in
any subject population, we randomized the resting-cell
activation parameter (a in Materials and Methods in the
section Modeling the Cellular Immune Response) over
subjects, multiplying it by a log-normal random variable with
mean one and standard error 2.0. As a consequence of the
programmed-proliferation assumption (rendering the im-
mune system a ‘‘high-Q’’ ampliﬁer, in engineering language),
the effect on the steady-state immune response is substantial
and the viral load becomes distributed also as log-normal
with deviation of several logs (see Figures 4 and 5), as has been
observed in cohorts of patients in the chronic stage of
infection [14]. For each subject, an initial stochastic simu-
lation determined the infection status (at 30 days); in the
infected case, it was followed by a deterministic simulation to
compute the viral load (at 120 days). The initial conditions for
the stochastic simulation were as described above, assuming a
volume V ¼ 15 ll. We ﬁxed the initial condition for the
deterministic simulation at 100 ITs; as the model exhibits a
stable steady state, this choice mattered little.
Here we report on the performance of statistical estima-
tion for three hypothetical vaccine scenarios. The initial
conditions on the immune system refer to the deterministic
simulation used to compute the viral load.
Case 1.
The death rate of natural HIV-speciﬁc memory cells was .33
per day (‘‘defective memory’’ scenario); there were 10
5 naı ¨ve,
HIV-speciﬁc CD8s, but no memory cells in either vaccinated
or placebo subjects.
Case 2.
The death rate of natural HIV-speciﬁc memory cells was .33
(‘‘defective memory’’ scenario); there were 10
5 naı ¨ve HIV-
speciﬁc CD8s in both groups and 10
9 vaccine-raised memory
cells in vaccinated subjects but none in placebo subjects.
Case 3.
The death rate of vaccine-induced HIV-speciﬁc memory
cells was .00017 (‘‘defective memory’’ cured); there were 10
9
memory (but no natural) HIV-speciﬁc CD8 cells in the
vaccinated subjects and 10
5 naı ¨ve but no memory cells in
unvaccinated subjects.
The true VE for prevention in each case was 0.51 (by
simulation, using the stochastic model). In Case 1, there was
no causal vaccine effect on viral load, and so any estimated
effect must be due to selection bias. In Case 2, since the
‘‘defect’’ was not cured we expect to see only a modest effect
on viral load. (Due to the stability of the steady state, effects
of initial conditions are transient.) In Case 3, there was a large
causal vaccine effect on viral load.
For each case, for each of the 500 vaccine trials, VE was
estimated as one minus the ratio of proportions of vaccine
and placebo recipients infected, and the ACE(b)w a s
estimated using the GBH method for b ¼  1,0,1,2. For all
three scenarios, the average VE estimate over the 500 trials
was 0.57, close to the true 0.51. Figure 6 summarizes the
results on estimation of ACE(b). For Case 1, the analysis that
Figure 4. Histogram of Viral Loads, Generated from Variable Activation
Parameter (a)
DOI: 10.1371/journal.pcbi.0020064.g004
Figure 5. QQplot of Viral Loads, Generated from Variable Activation
Parameter (a) against a Normal Law
DOI: 10.1371/journal.pcbi.0020064.g005
Figure 3. Vaccine Efficacy for Prevention as a Function of V, as Simulated
from the Small-Volume, Stochastic Model for Three Values of R0
The EPV was moderate (see Table 1 footnote), yielding a probability of
infection-given exposure that ranged from 0.01–0.2, depending on V
and R0.
10,000 stochastic simulations were used to produce each point in this
figure.
Circles, R0 ¼ 4; squares, R0 ¼ 10; and diamonds, R0 ¼ 20.
DOI: 10.1371/journal.pcbi.0020064.g003
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Modeling Vaccine Efficacyassumes no selection bias (b¼0) shows that the setpoint viral
load is about a third log higher on average in infected
vaccinees than in infected placebos. However, once possible
selection bias is accounted for, the causal vaccine effect on
viral load is seen to be consistent with nullity (b ¼ 0 panel).
Therefore, the GBH method leads to the conclusion of no
causal vaccine effect, thereby protecting against spuriously
concluding harm by vaccine. The methods applied to Case 2
provide a similar conclusion. In contrast, for Case 3 the
estimated ACE(b) ranges from about 0.8 (at b¼ 1) to 1.5 (at b
¼ 2), with the lower 95% conﬁdence limits always exceeding
0.0, so that the method correctly concludes a beneﬁcial causal
vaccine effect to lower viral load, robust to plausible levels of
selection bias. The GBH methods for estimating the causal
effect of vaccine on viral load therefore pass these three tests
posed by mechanistic, model-based, and simulated trials.
Discussion
Novel causal inference methods will be applied to analyze
the viral load primary endpoint in the ﬁrst two efﬁcacy trials
of a T cell HIV vaccine. But the operating characteristics of
these methods in plausible biological scenarios have not been
studied. This article described novel mechanistic models of
CTL and HIV kinetics which provided biologically grounded
simulations of the STEP trials. We found that the causal
methods provided inferences that accurately reﬂected the
assumed mechanisms. The mechanistic models, in particular
the small-volume, stochastic case, also yielded the (surprising)
conclusion that memory T cells might, in a natural setting (as
opposed to animal trials with huge inoculums), abort an HIV
infection.
The process used to elicit a range of plausible values for the
sensitivity parameter for estimating the ACE was as follows:
Shepherd, Gilbert, and Mehrotra [unpublished data] sent a
letter to 10 HIV vaccine experts, with approximately ﬁve
pages of discussion of the interpretation of the sensitivity
parameter, and asked each expert to provide their opinion on
minimum and maximum plausible values. Eight of the ten
experts responded. This information will be used in the
analysis of the Merck/HVTN vaccine efﬁcacy trial.
What are the advantages or disadvantages of GBH’s method
(via expert-elicited parameter) relative to other approaches
to assessing efﬁcacy of a T cell vaccine? A leading alternative
primary analysis is to compare the ‘‘burden-of-illness’’
between vaccine and placebo recipients, including all
randomized subjects in the analysis, and to assign a value of
zero for the viral loads of uninfected subjects [45]. The
advantage of this analysis is that it provides unbiased
inferences on a causal effect. One disadvantage is that it
aggregates the vaccine effects on infection and viral load, so
that other methods that assess infection and viral load
separately are needed to address mechanisms of protection.
A second is that it has low power compared with the GBH
causal inference approach that conditions on infection. The
much lower power was documented in extensive simulations
[13] and occurs because the majority of subjects are not
infected during the trial. Both methods are, of course, free
from questionable biological assumptions that are inevitable
in any mechanistic model. Presumably no vaccine will be
licensed based on model-based data analysis in the near
future. On the other hand, models make explicit assumptions
that can be criticised or accepted, unlike expert opinion
whose basis may be unclear.
The many alternatives to our biological assumptions
suggest new directions for research. The scenario we
developed for prevention of infection in the Introduction
linked a low effective population size to EPV in virion
Figure 6. Boxplots of the ACE(b) Estimates
For the 500 simulated STEP vaccine trials per case, each panel shows a boxplot of the ACE(b) estimates (middle boxplot), and boxplots of the lower and
upper 95% confidence limits for ACE(b).
(A–D) Case 1.
(E–H) Case 2.
(I–L) Case 3.
DOI: 10.1371/journal.pcbi.0020064.g006
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Modeling Vaccine Efficacyproduction and to the small observed probability of infection
given exposure. An alternative explanation for the latter is
stochastic breach of a mucosal barrier. In this scenario,
presumably either a large number of or no PITs at the
mucosal site would be expected at each exposure. The
increased risk associated with genital ulcers or abrasions
during sexual activity supports this theory, while the risk
associated with non-ulcerative genital infections might be
taken as supportive of the stochastic-extinction theory (by
recruiting memory activated CD4s to the mucosal membrane,
the STD would enhance the probability of making a
‘‘successful’’ PIT) [46].
Concerning that ﬁrst PIT (or PITs), several groups have
endeavored to determine the infection probability as a
function of inoculum size in animal models [47–50]. With
some additional model development and biological hypoth-
eses, data from repeated low-dose exposures might be
converted into information about the PIT distribution. In
this regard, the observations of Ritola et al. [51], of several
variants of the envelope protein making an appearance
during primary infection are interesting. As the authors
remark, the ﬁnding that two or three variants appear almost
as frequently as one is inconsistent with a free-virion route
and a low probability of infection (implying the Poisson law).
However, Jung et al. [52] discovered that HIV-infected T cells
harbor an average of 3.6 proviruses, frequently with distinct
genomes; hence the observations of Ritola et al. [51] are
consistent with infection by one initial cell. The assumption
in the stochastic model of one initial PIT is of course the
simplest; but if there are N initial PITs per exposure,
distributed as a Poisson random variable with mean I, for
example, and the outcomes of the different local infections
are independent, the prevention probability becomes exp
(Ifpab.   1g), where pab is the (simulation-derived) probability
of aborting an infection chain with one initial PIT. If,
however, the infections are contiguous (e.g., at the same
mucosal surface), the processes are not independent (because
both activate and are recognized by the same CTLs), and the
probability can only be learned through simulations.
With respect to model realism and simulation technique,
when more data—and faster computers—become available,
the compartmental design of the small-volume model should
be replaced by an agent-based approach. One motivating
factor is the unrealistic time-to-event distributions in Markov
models—which must, by the assumed Markov property, be
exponential. For modeling biology, this means that lifetimes
have implausibly heavy tails, and the additional perverse
effect that individuals die but cannot age. In our context,
another peculiar consequence concerns the number of
virions produced by a PIT, which we might expect to have a
Poisson distribution—but, in Markov models, it must be
geometric (because the PIT lifetime must be exponential).
Thus, compartmental models already exhibit a (moderate)
degree of EPV. Adding more compartments can partly
restore realism, by converting exponentials to gammas [53];
but the heavy-tail problem persists. By contrast, in agent-
based models, arbitrary time-to-event distributions can be
incorporated; when interest centers on tail events (such as
extinctions), changing over might have substantial impact.
Indeed, we built an agent-based simulator for the small-
volume stochastic model and noted—adopting a Weibull
distribution, with exponent three (which has a much lighter
tail) for all lifetimes—increased extinction rates. However, at
present we lack data on the proper time-to-event distribu-
tions for T cell kinetics, and the agent-based routine is 100
times slower than for the compartmental model, rendering
simulating thousands of trials a daunting task.
Materials and Methods
Estimating the ACE of vaccination on viral load. We brieﬂy present
the statistical details of GBH’s method for estimating the ACE of
vaccination on viral load. The method is formulated using the
potential outcomes framework for causal inference [32,54]. Let Z be
the vector of vaccination assignments for the N randomized subjects,
with ith element Zi (Zi¼v, vaccine; Zi¼p, placebo). Let S(Z) be the N-
vector with ith element Si(Z), which is the indicator of whether the ith
subject would be infected given Z. For subjects with Si(Z) ¼ 1, let
Yi(Z,S) be the potential viral load if assigned Z, given S ¼ S(Z). We
adopt Rubin’s Stable Unit Treatment Value Assumption (SUTVA;
[54]), which states that Si(Z) ¼ Si(Z9) whenever Zi ¼ Zi9, and Yi(Z,S) ¼
Yi(Z9,S9) whenever Zi ¼ Zi9 and Si(Zi) ¼ Si9(Zi) ¼ 1. SUTVA implies that
the potential outcomes (Si(v),Si(p),Yi(v),Yi(p)) of each subject i are
unrelated to the assignment Zj of other subjects, and allows Si(Z) and
Yi(Z,S) to be written as Si(Zi) and Yi(Zi), respectively. Under SUTVA,
each subject has two potential infection outcomes (Si(v), Si(p)) and at
most two potential viral load outcomes (Yi(v),Yi(p)). For each subject,
only one of Si(v)o rSi(p) is observed, denoted Sobs
i [ Si(Zi), and in
the subgroup with Sobs
i ¼ 1, Yobs
i [ Yi(Zi) is observed. Note that Yi(Z)i s
deﬁned only if Si(Z) ¼ 1.
Any comparison between the ordered sets fYi(v):Si(v) ¼ Si(p) ¼1g
and fYi(p):Si(v)¼Si(p)¼1g is a causal effect, because it is made within
a subgroup of subjects with common joint values of (Si(v),Si(p))
(Property 2 in [32]). GBH referred to the subgroup fSi(v)¼Si(p)¼1g as
the ‘‘always-infected’’ principal stratum, as it comprises subjects who
would be infected no matter whether they received vaccine or
placebo. Let
F
alw:inf
ðvÞ ðyÞ[PrðYiðvÞ yjSiðvÞ¼SiðpÞ¼1Þð 1Þ
F
alw:inf
ðpÞ ðyÞ[PrðYiðpÞ yjSiðvÞ¼SiðpÞ¼1Þ; ð2Þ
and assume the Yi(v) are identically distributed as F
alw:inf
ðvÞ ð Þ;
and the Yi(p) are identically distributed as F
alw:inf
ðpÞ ð Þ. Any func-
tional that measures a contrast of F
alw:inf
ðvÞ ð Þ and F
alw:inf
ðpÞ ð Þ is a
causal effect, and GBH focused on the ACE estimand, deﬁned as
ACE ¼
Z ‘
 ‘
yfdF
alw:inf
ðpÞ ðyÞ dF
alw:inf
ðvÞ ðyÞg ð3Þ
Because neither distribution in Equations 1 and 2 are identiﬁable
(since Si(v) and Si(p) are not both observed), assumptions are needed
to be able to estimate ACE. In addition to SUTVA, GBH made the
following two assumptions for identifying the distributions:
A1: The assignment Zi of each subject is independent of his/her
potential outcomes (Si(v),Si(p),Yi(v),Yi(p)).
A2: For each subject i, Pr(Si(v) ¼ 1,Si(p) ¼ 0) ¼ 0.
Assumption A1 plausibly holds in HIV vaccine efﬁcacy trials due to
randomization and blinding. A2 states that no subject would be
infected if randomized to vaccine but uninfected if randomized to
placebo, and under A1 will hold if vaccination does not increase the
per-exposure infection probability for any trial participant.
Assumption A2 implies that all infected vaccine recipients are in
the always-infected principal stratum, so that F
alw:inf
ðvÞ (y) ¼ Fv(y) [
Pr(Yobs
i   yjSobs
i ¼1,Zi¼v), where Fv( ) is the distribution of viral load in
infected vaccine recipients; therefore F
alw:inf
ðvÞ ( ) is identiﬁed from the
observed data. A1 and A2 do not identify F
alw:inf
ðpÞ ð Þ, however, because
they do not determine whether an infected placebo recipient is in the
‘‘protected’’ fSi(v)¼0,Si(p)¼1g or always-infected fSi(v)¼1,Si(p)¼1g
principal stratum. To identify F
alw:inf
ðpÞ ( ), GBH supposed a semi-
parametric model relating it to Fp( ), the identiﬁed distribution of
viral load in infected placebo recipients:
F
alw:inf
ðpÞ ðyÞ¼W 1
Z y
 ‘
wðuÞdFpðuÞ; ð4Þ
where w(y) ¼ Pr(Si(v) ¼ 1jYi(p) ¼ y,Si(p) ¼ 1) and W ¼
R ‘
 ‘w(u)dFp(u)i sa
normalizing constant. The weight function w(y) is the probability that
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infected if randomized to vaccine. If w( ) were known, then both
F
alw:inf
ðvÞ ( ) and F
alw:inf
ðpÞ ( ) would be identiﬁed, and the ACE could be
estimated. However, w( ) is unknown, and the data plus A1–A2 do not
inform about whether a particular w( ) is correctly speciﬁed.
Accordingly, GBH assumed w( ) is a known cumulative distribution
function, and recommended estimating ACE for a variety of ﬁxed
choices of w( ) as a form of sensitivity analysis. GBH focused on w( )
equal to the inverse logit function, w(y)¼w(y j a,b)¼expfaþbyg/(1þ
exp faþbyg), which allows w( ) to be constant or smoothly monotone
increasing or decreasing. For b ﬁnite, exp(b) is the odds ratio of
infection under randomization to vaccine given infection under
randomization to placebo with viral load y versus with viral load y 1.
This interpretation allows the choice of b to be guided by beliefs
about plausible degrees of selection bias.
Given ﬁxed b, a is determined as the solution to the equation
F
alw:inf
ðpÞ (‘jb)¼1. Fixing b¼0 speciﬁes a constant weight w(y j a,b¼0)¼
W, and reﬂects an assumption of no selection bias. Fixing b . 0 makes
w(y j a,b) monotone increasing in y and reﬂects ‘‘positive’’ selection
bias, with infection odds under randomization to vaccine higher for a
larger potential viral load Y(p) ¼ y. Similarly, b , 0 makes w(y j a, b)
monotone decreasing in y and reﬂects ‘‘negative’’ selection bias, with
infection odds under randomization to vaccine lower for a larger y.
Ranging b from  ‘ to ‘ spans all possible magnitudes of selection
bias parametrized by w( ).
To describe the estimator of ACE(b) developed by GBH, let nv(np)
be the number of infected subjects in the vaccine (placebo) arm, and
Yv1, ... , Yvnv(Yp1) ... Ypnp) be the viral loads in infected vaccine
(placebo) recipients. For a given b, the semiparametric maximum
likelihood estimator d ACE(b)o fACE(b) is given by
d ACEðbÞ¼
Z ‘
 ‘
yfd^ F
alw:inf
ðpÞ ðyjbÞ d^ FvðyÞg; ð5Þ
where
R ‘
 ‘ yd^ FvðyÞ¼n 1
v
Pnv
i¼1Yvi and ^ F
alw:inf
ðpÞ (y j b) is the maximum
likelihood estimator of F
alw:inf
ðpÞ (y j b) under the model described in
Equation 4, calculated as
^ FðpÞðyÞ¼ð 1   c VEÞ
 1 1
np
X np
i¼1
IfYpi   ygwðYpij^ a;bÞ; ð6Þ
where c VE is the maximum of zero and one minus the ratio of
infection rates (vaccine/placebo), and ^ a is computed as the solution to
the equation ^ F
alw:inf
ðpÞ (‘ j b) ¼ 1 as a function of a. Semiparametric
bootsrap percentile conﬁdence intervals about ACE(b)c a nb e
computed by resampling from ^ FvðyÞ and ^ F
alw:inf
ðpÞ (y j b). Computing
point and interval estimates of ACE(b) for a range of ﬁxed values of b
constitutes a sensitivity analysis. We used 500 bootstrap samples.
Modeling the infection process. We used a simpliﬁed version of the
compartmental model, proposed in [24], adapted, in the stochastic
case, to incorporate various types of infected cells. (Only one type is
required for the deterministic model.) Each type has two life stages.
The ﬁrst stage, labelled Xk, where k denotes the type, represents the
count of IT or ‘‘eclipse’’-phase cells, before virions appear, and the
second, labelled Yk, the count of PIT cells. The possible jumps and
rates are described in Table 1.
In the presence of the immune response, dPIT (inverse PIT lifetime)
was modiﬁed to dPITþjCTLs, where CTLs and j are deﬁned as in the
next section, Modeling the Cellular Immune Response. We derived
the infection rate i from the basic reproductive number, R0:
i ¼
R0 dPIT
M
; M ¼
X
vk pk: ð7Þ
With this deﬁnition, the growth rate of infection (sum of Xs and Ys)
is governed by the eigenvalue (let d ¼ dPIT):
k ¼
 ðg þ dÞþ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðg þ dÞ
2 þ 4gd½R0   1 
q
2
: ð8Þ
We chose R0 in the range 4–6 (except in Figure 3, which explores a
wider span), which with the other parameters in Table 2 yields a
doubling time (log2/k) in the range 0.88–1.3 days, and time-to-peak
viremia (assuming 7 logs growth) of 20–30 days, consistent with
observations of HIV before the peak [56,57]. (One investigation, [56],
reported a much shorter doubling-time at early timepoints, and
much larger R0, but these estimates were derived from an
extrapolation using a target cell–limited rather than an immune-
control model.) As our goal is to investigate the statistical properties
of methods that assume CTL control, we adopt the latter. For other
discussions of TCL and IC in primary infection, see [9,58]. In the
statistical study we used R0¼4, as it creates the maximal bias and the
largest opportunity for the method to fail.
For the production rates, with three types (the simplest non-trivial
case), we usually chose v1 ¼ 0, v2 ¼ 1, v3 ¼ K, and
p3 ¼
3Fmean
K
; ð9Þ
p2 ¼ 3ð1   Fmean Þ; ð10Þ
p1 ¼ 1   p2   p3: ð11Þ
Here Fmean is the fraction of the mean contributed by the third
type. Choosing Fmean to be nearly one avoids trivial cases where the
third type contributes inﬁnitesimally to the infection rate. Note that
this construction yields mean virion production M ¼ 3 independent
of K and Fmean. Table 2 records our parameter values for the
infection process.
Modeling the cellular immune response. Again, we used a
simpliﬁed version of the compartmental model introduced in [24].
Let Wi denote HIV-speciﬁc CD8 compartments. The allowed
transitions are described in Table 3.
Let NR be the index of the naı ¨ve resting compartment; MR, the
memory resting compartment; and nd the number of permitted
doublings. In the jumps labelled mitoses, the index ranges over i ¼
NR, ..., NR þ nd   1o rMR, ..., MR þ nd   1; in the jumps labelled
deaths, i ¼ NR,MR,NR þ nd or MR þ nd; in the jumps labelled
reversions, i¼NRþnd 1 and j¼MR. Activation into the cell cycle of
resting, naı ¨ve, or memory CD8s occurs at rate mNR ¼ a PITS or mMR ¼
a[memory-factor] PITs,w h e r e‘‘PITs’’ denotes
P
Yk (from the
previous section ‘‘Modeling the infection process’’); otherwise, mi ¼
1/ (cell-cycle time). The CTLs appearing in section 1 are the sum of Wi
for i¼NRþ4, ...NRþnd (naı ¨ve CD8s promote to effector status after
four divisions) or i ¼ MR þ 1, ... MR þ nd (memory promote after
one). We set f (thymic immigration of resting, naı ¨ve HIV-speciﬁc
CD8s) ¼ WNR (at time zero) 3 dNR, implying a steady-state immune
system, absent activation. When only vaccine-induced cells are
involved, as when simulating the infection probability, the naı ¨ve
compartments (Wi, for i ¼ NR, ... ,NR þ nd) are deleted from the
model. We summarize our immune system parameters, which assume
an HIV infection, HIV-speciﬁc CD8s, and the ‘‘defective memory’’
scenario, in Table 4. See [24] for the scenario and references to the
literature.
Simulating from the models. When employing the deterministic
models, we simulated from the ODEs deﬁned by
dCi=dt ¼
X
jumps
ðrateÞDjump Ci; ð12Þ
Here Ci ¼ Xi, Yi,o rWi is any model compartment and D is the
difference operator corresponding to the jump. To update in the
deterministic model, we used a time-step of .01 day and fourth-order
Runge–Kutta. We simulated the jump processes (used for computing
the infection probability) by the ‘‘direct’’ method [43]: drawing
exponential waiting times for all transitions according to the (inverse)
rates at each time; determining which was the next jump;
implementing it; then updating all rates. The program was written
in C language and is available from the ﬁrst author. Simulating 500
trials required about three days using one processor (a 3.06-GHz,
Intel Xeon) of a Pentium workstation.
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